Baker McKenzie Advises Servier on $2.5 Billion Acquisition of Day One Biopharmaceuticals

"Baker McKenzie advised French pharma group Servier on its acquisition of US Nasdaq‑listed Day One Biopharmaceuticals for about $2.5 billion. Day One develops targeted therapies for serious cancers in adults and children; the deal strengthens Servier’s oncology portfolio and addresses unmet therapeutic needs. Servier will launch a cash tender offer at $21.50 per share, with any remaining shares to be absorbed in a subsequent merger at the same price. The transaction is expected to close in Q2 2026, subject to customary conditions. Baker McKenzie’s lead advisers were Mike DeFranco, Michelle Carr and Piotr Korzynski (Chicago) and Stephane Davin (Paris); Servier’s deal team was led by Olivier Madec, Benoît Chéron and Nicolas Mavel."